Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
13
pubmed:dateCreated
2009-9-25
pubmed:abstractText
Multiple myeloma (MM) is a cancer of plasma cells with complex molecular characteristics that evolves from monoclonal gammopathy of undetermined significance, a highly prevalent premalignant condition. MM is the second most frequent hematologic cancer in the United States, and it remains incurable, thereby highlighting the need for new therapeutic approaches, particularly those targeting common molecular pathways involved in disease progression and maintenance, shared across different MM subtypes. Here we report that Wnt/beta-catenin is one such pathway. We document the involvement of beta-catenin in cell-cycle regulation, proliferation, and invasion contributing to enhanced proliferative and metastatic properties of MM. The pleiotropic effects of beta-catenin in MM correlate with its transcriptional function, and we demonstrate regulation of a novel target gene, Aurora kinase A, implicating beta-catenin in G2/M regulation. beta-catenin and Aurora kinase A are present in most MM but not in normal plasma cells and are expressed in a pattern that parallels progression from monoclonal gammopathy of undetermined significance to MM. Our data provide evidence for a novel functional link between beta-catenin and Aurora kinase A, underscoring a critical role of these pathways in MM disease progression.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1528-0020
pubmed:author
pubmed:issnType
Electronic
pubmed:day
24
pubmed:volume
114
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2699-708
pubmed:dateRevised
2011-7-11
pubmed:meshHeading
pubmed-meshheading:19652203-Animals, pubmed-meshheading:19652203-Cell Cycle, pubmed-meshheading:19652203-Cell Proliferation, pubmed-meshheading:19652203-Disease Progression, pubmed-meshheading:19652203-Drug Resistance, Neoplasm, pubmed-meshheading:19652203-Gene Expression Regulation, Enzymologic, pubmed-meshheading:19652203-Gene Expression Regulation, Neoplastic, pubmed-meshheading:19652203-Humans, pubmed-meshheading:19652203-Mice, pubmed-meshheading:19652203-Mice, Inbred NOD, pubmed-meshheading:19652203-Mice, SCID, pubmed-meshheading:19652203-Mice, Transgenic, pubmed-meshheading:19652203-Multiple Myeloma, pubmed-meshheading:19652203-Protein-Serine-Threonine Kinases, pubmed-meshheading:19652203-Transplantation, Heterologous, pubmed-meshheading:19652203-Tumor Cells, Cultured, pubmed-meshheading:19652203-Wnt Proteins, pubmed-meshheading:19652203-beta Catenin
pubmed:year
2009
pubmed:articleTitle
Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression.
pubmed:affiliation
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't